For subscribers
US pharma giant's investment in S'pore will reinforce drug supply chain, boost new vaccine production
Sign up now: Get ST's newsletters delivered to your inbox
The syringe and vial-packing section in MSD’s current manufacturing facility in Tuas.
ST PHOTO: GAVIN FOO
Follow topic:
SINGAPORE - MSD's new investment here will put Singapore at the heart of its revamped global supply chain from where the US drugmaker will produce and distribute its latest innovative medicine and vaccines.
The new manufacturing facilities and investments in digitalisation and automation will enhance distribution capabilities, lowering the risk of supply disruptions, said Mr David Peacock, the Asia-Pacific president of MSD - a firm known as Merck & Co in the United States and Canada.
